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Background
Reports of indeterminate lupus anticoagulant (LAC) results are common; however, no 
published data on their prevalence or clinical significance are available. We investigated 
the prevalence and clinical characteristics of patients with indeterminate LAC.
Methods
We retrospectively reviewed the clinical and serologic characteristics of 256 unselected 
patients with LAC results.
Results
Indeterminate results were observed in 32.7% of LAC profiles that were least frequent 
(25.4%) when activated partial thromboplastin time (aPTT) was normal, most frequent 
(39.8%) when aPTT was elevated, and were observed in 35% of patients taking warfarin. 
The final indeterminate LAC cohort included 65 patients with a mean follow-up of 18 
months. Malignancy and autoimmune disease were present in 29% and 25% of patients, 
respectively. The most common thrombotic events were deep vein thrombosis (DVT) 
(28%), cerebral ischemic stroke (14%) and pulmonary embolism (14%). Patients with in-
determinate results were more likely to be men, older, and with a history of DVT, superficial 
thrombosis, or myocardial infarction than patients with negative tests (N=106). 
Concurrent warfarin therapy was more prevalent in the indeterminate group, but was 
not statistically significant. In the multivariate analysis, none of the variables showed stat-
istical significance. During follow-up, 10 of 16 patients with indeterminate results showed 
change in classification upon retesting.
Conclusion
Patients with indeterminate LAC results were common, and their clinical characteristics 
differed from those with negative results. There is a need for a prospective study of the 
clinical history of patients with indeterminate LAC results.
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INTRODUCTION
Antiphospholipid (aPL) antibodies are a group of heteroge-
neous autoantibodies against phospholipid (PL)-bound 
proteins. Conley and Hartman [1] first described circulating 
anticoagulants in patients with systemic lupus erythematosus 
(SLE) in 1952. The term, lupus anticoagulant (LAC), was 
first used by Feinstein and Rapaport [2] in 1972 to describe 
antibodies that inhibited PL-D coagulation in vitro. The term 
“ L A C  a s s a y ”  i s  a  d o u b l e  m i s n o m e r ,  b e c a u s e  i t  i s  n e i t h e r  
a test for lupus nor a test for a natural anticoagulant. In 
fact, the various “LAC assays” are tests that detect im-
munoglobulins against PL-binding proteins that inhibit coag-
ulation in vitro, but are clinically associated with thrombosis.
LAC is a well-established risk factor for thrombosis [3, 
4]. The International Society of Thrombosis and Hemostasis 
(ISTH) criteria for the diagnosis of LAC include the follow-
ings: a screening test that demonstrates prolongation of PL-D 
clotting time; a mixing test that confirms the presence of 
an inhibitor; confirmation that the inhibitor is PL-D; and 
the exclusion of other coagulopathies [5]. These criteria were Korean J Hematol 2011;46:239-43.
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recently updated by the ISTH to clarify the acceptable test 
types and the interpretation of cut-off values [6]. Most pub-
lished epidemiologic studies investigating the clinical associ-
ations of LAC with thrombosis have only included cases 
meeting all 4 laboratory diagnostic criteria. However, since 
LAC testing includes screening tests, mixing studies, and 
phospholipid neutralization assays, not all test results will 
be concordant, and samples are not always clearly positive 
or negative for the presence of LAC. Patients with test results 
that fulfill some, but not all, of the criteria are often consid-
ered to show negative results for LAC. However, the preva-
lence of patients whose testing results fulfill some but not 
all ISTH criteria, a so-called “indeterminate LAC” result, 
and its clinical implications are still unclear.
We retrospectively studied one of the largest known co-
horts of patients with indeterminate LAC results from a 
single referral center to determine the prevalence, clinical, 
and serologic features of this group.
MATERIALS AND METHODS
This study investigated the prevalence of thrombotic 
events in an initial cohort of unselected patients (N=256), 
who were tested for LAC and other aPL antibodies over 
a 2-month period from one tertiary hospital in the United 
States. The laboratory results of prothrombin time/interna-
tional normalized ratio (PT/INR), activated partial thrombo-
plastin time (aPTT), dilute Russell's viper venom time 
(DRVVT), hexagonal phase PL neutralization (STACLOT, 
Diagnostica Stago, Parsippany, NJ, USA), and platelet neutral-
ization procedure (PNP) were evaluated in all patients. The 
profile included 3 screening assays (aPTT [Actin FSL, Siemens 
and STACLOT Screen] and DRVVT screen [Precision 
Biologic]), 2 mixing studies (aPTT 1:1 mix and DRVVT 1:1 
mix), and 3 separate PL-D assays [DRVVT confirm, 
STACLOT, and PNP (Precision Biologic)]. Samples contain-
ing ＞0.1 U/mL heparin were pre-treated with Hepadsorb 
to neutralize heparin activity. The LAC profile was consid-
e r e d  i n d e t e r m i n a t e ,  i f  1  o r  m o r e  P L - D  t e s t  r e s u l t s  w e r e  
positive, but the aPTT or DRVVT mixing study was negative.
The initial cohort included 256 patients, and 83 had in-
determinate results. From this group, 18 patients were ex-
cluded: 4 due to incomplete data, 2 due to high heparin 
levels (anti-Xa ＞1.0 U/mL), 5 due to other prothrombotic 
etiologies, and 7 with other positive aPL antibodies (aCLs 
[anticardiolipin antibodies] or anti-β2 GPIs [anti-β2 glyco-
protein I antibodies]). To assess their thrombotic history, 
we performed retrospective chart reviews and tabulated all 
the Sapporo clinical features, malignancies, and autoimmune 
disorders 5 years before and 2 years after the index laboratory 
testing. Events that did not fulfill diagnostic criteria for 
thrombosis, ischemic events, or obstetrical complications 
were excluded. The final analysis sample (after applying 
the exclusion criteria) included 65 patients with in-
determinate LAC, 27 with positive LAC, and 106 negative 
for LAC.
A protocol form was used to record the clinical and labo-
ratory characteristics of the patients. The information in-
cluded demographic patient characteristics, disease-related 
data (underlying disease, site of thrombosis, associated clin-
ical manifestations, and precipitating factors), family history, 
laboratory features, and the presence of inherited or acquired 
prothrombotic disorders. Standardized clinical and labo-
ratory data collected on the protocol form were transferred 
to a designated computerized database (Excel/Microsoft).
Statistical tests were performed using GraphPad software 
2005 (GraphPad Software, Inc., La Jolla, CA, USA). The 
Student’s t test was used to compare mean values using a 
two-tailed analysis. Associations between categorical varia-
bles were tested using the χ
2 test or Fisher’s exact test when 
required. Differences were considered statistically significant 
at when P＜0.05.
RESULTS
1. General characteristics
Among the final cohort of 65 patients with indeterminate 
LAC results, 30 (46%) were male and 35 (54%) were female. 
The median age was 57 years, with a mean±SD of 54.5±1.8 
years. Active malignancy and myeloproliferative disorders 
were present in 19 patients (29%), and 16 (25%) had an 
underlying autoimmune disease. The most common auto-
immune disease was SLE in 4 patients (6%). Patients in 
this group had a median follow-up of 22 months, with a 
mean of 18±12.8 months.
2. Clinical manifestations
Of the 65 patients with indeterminate LAC results, 18 
patients (28%) had a history of venous thrombosis, 16 (25%) 
had arterial thrombosis, and 3 (5%) had mixed arterial and 
venous thrombosis. The most common thrombotic event 
was deep vein thrombosis (DVT) in 18 patients (28%), fol-
lowed by cerebral ischemic stroke and pulmonary embolism 
(PE) in 9 patients (14%) each, and transient ischemic attack 
(TIA) in 6 patients (9%). Other venous events were superficial 
thrombosis (ST) in 11 patients (17%), hepatic thrombosis 
in 1 patient (1.5%), and cerebral venous thrombosis in 1 
patient (1.5%). A history of myocardial infarction (MI) was 
documented in 9 patients (14%) within 5 years from initial 
testing. Renal infarction was observed in 2 patients (3%), 
and ischemic colitis in 1 patient (1.5%). The most frequently 
associated nonthrombotic manifestations were hematological 
disorders, which were present in 6 patients (9%); the most 
frequent of these was thrombocytopenia in 4 patients (6%). 
One patient (1.5%) had toxemia, but no other obstetrical 
complications. Four patients (6%) in this group died: 1 due 
to PE and sepsis; 1 due to infective endocarditis; and 2 had 
no documented cause of death.
3. Immunologic features
The unselected initial referred cohort included 256 pa-
tients, 2 of which were excluded due to high heparin levels. Korean J Hematol 2011;46:239-43.
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Table 1. LAC profiles of all patients (excluding those with high heparin levels).
LAC Interpretation N (%) Normal aPTT (%) High aPTT (%) Warfarin (%)
Negative 133 (52) 91 (72) 42 (33) 27 (40)
1 PL test+ 53 (21) 23 (18) 30 (23) 14 (21)
2 PL test+ 24 (9) 9 (7) 15 (12) 9 (13)
3 PL test+ 6 (2) 0 (0) 6 (5) 1 (1)
LAC+ 38 (15) 3 (2) 35 (27) 17 (25)
Abbreviations: LAC, Lupus anticoagulant; aPTT, activated partial thromboplastin time; PL, phospholipid aPTT.
Table 2. General characteristics of patients according to LAC 
profile.
Indeterminate 
LAC
Negative 
LAC
Positive 
LAC
N 65 106 27
Age (mean±SD), yrs 54.5±18
a) 47.2±21 51.1±16.4
Female/Male 35/30
a) 74/32 13/14
Malignancy  19 (29%) 21 (20%) 8 (30%)
Autoimmune disease  16 (25%) 32 (30%) 8 (30%)
Warfarin therapy  21 (32%) 23 (22%) 12 (45%)
Hypertension  28 (43%) 41 (39%) 16 (59%)
Diabetes mellitus  11 (17%) 8 (8%) 10 (37%)
Hyperlipidemia  24 (37%) 30 (28%) 9 (33%)
Smoking    28 (43%)
a) 27 (25%) 12 (44%)
a)P＜0.05 vs. the negative results group. Surgery, renal disorders, 
and premature family history categories had ＜5 cases in each cell 
and were not analyzed because of the small sample size. 
Abbreviation: LAC, lupus anticoagulant.
Table 3. Thromboembolic events in patients according to LAC 
profile.
Indeterminate 
LAC
Negative 
LAC
Positive 
LAC
N 65 106 27
DVT 18  (28%)
a) 15 (14%) 11 (41%)
PE  9 (14%) 10 (9%) 3 (11%)
Stroke  9 (14%) 9 (8%) 4 (15%)
TIA  6 (9%) 2 (2%) 2 (7%)
Phlebitis 10  (15%)
a) 3 (3%) 2 (7%)
MI 9  (14%)
a) 5 (3%) 1 (4%)
a)P＜0.05 vs. the negative LAC group.
Abbreviations: LAC, lupus anticoagulant; DVT , deep vein throm-
bosis; PE, pulmonary embolism; TIA, transient ischemic attack; MI,
myocardial infarction.
Before applying any other exclusion criteria, 32.7% of these 
patients had indeterminate results. Indeterminate results 
were least frequent (25.4%) when the aPTT was normal, 
most frequent (39.8%) when the aPTT was elevated, and 
were observed in 35% of patients taking warfarin. In the 
53 patients with a single abnormal PL test, STACLOT was 
the most frequently abnormal test (28/53, 52.8%), followed 
by DRVVT (20/53, 37.7%), and PNP (5/53, 9.4%). These 
findings are summarized in Table 1.
In the initial group of patients with indeterminate results 
(N=83), aCLs or anti-β2 GPIs were detected in 7 patients 
(8%). Inherited prothrombotic disorders were found in 4 
patients (5%), including heterozygosity for factor V Leiden 
(N=1) and heterozygosity for prothrombin G20210A (N=2). 
One patient had heparin induced thrombocytopenia syn-
drome (HIT).
4. Differences between patients with indeterminate LAC and 
those with negative results
Comparison between patients with indeterminate LAC 
tests and those with negative results is summarized in Tables 
2 and 3. Patients in the indeterminate group were relatively 
older (54.5±18 vs. 47.2±21 years), and this difference was 
statistically significant (P=0.02). These patients were also 
more likely to be male (P=0.049). History of DVT and ST 
of the extremities was significantly higher in the in-
determinate group (P=0.04 and 0.005, respectively). History 
of MI was also significantly more prevalent in the in-
determinate group (P=0.045). Concurrent oral anticoagulant 
therapy with warfarin was seen in 32% of patients in the 
indeterminate group compared to 22% of patients with neg-
ative results; however, it did not reach statistical significance 
(P=0.15). Although malignancies and immune disorders have 
been associated with aPL antibodies [7], there was no sig-
nificant difference between the 2 groups (P=0.19 and 0.48, 
respectively). In the multivariate analysis model (age, gender, 
malignancy, immune disease, DVT, and warfarin therapy), 
none of the variables reached statistical significance between 
the indeterminate LAC and negative result groups. 
Comparing these clinical variables between patients with 
indeterminate results and those with positive LAC from the 
s a m e  c o h o r t  f a i l e d  t o  s h o w  any significant differences.
DISCUSSION
In 1983, Hughes first described patients with a combina-
tion of certain clinical features and aPL antibodies [8]. 
Multiple aPL antibodies have been identified since then; 
however, LAC is probably the strongest risk factor for throm-
bosis [4]. To establish a laboratory diagnosis of LAC, the Korean J Hematol 2011;46:239-43.
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test results must fulfill all of the abovementioned ISTH cri-
teria, including a positive screening test, mixing studies, and 
phospholipid dependence. Patients with test panels that meet 
some, but not all criteria are considered indeterminate, and 
are usually not enrolled in epidemiological or therapeutic 
studies. This is the largest cohort of patients with indetermin-
ate LAC results studied for clinical associations. To date, 
no previous studies have determined the prevalence of in-
determinate LAC results and its clinical significance.
Indeterminate results were found to be common among 
patients referred for LAC evaluation, and were seen in 32.7% 
of all LAC profiles. Indeterminate results were most prevalent 
when the aPTT was elevated (39.8%) and in patients taking 
warfarin (37.5%). Accurate testing for LAC may be compro-
mised by anticoagulant medications, including warfarin, pos-
sibly due to low factor X levels causing false positive results 
[9, 10]. For this reason, the revised guidelines for diagnosis 
of the aPL syndrome recommend postponing laboratory in-
vestigation until discontinuation of treatment [11]. Concur-
rent warfarin therapy was seen in 29% of patients with 
indeterminate results and in 20% of those with negative 
results; however, both before and after applying the exclusion 
criteria, there was no significant difference in prevalence 
of warfarin therapy between the 2 groups. Olteanu et al. 
[12] recently showed that warfarin does not interfere with 
LAC detection by DRVVT. Heparin contamination is also 
a common problem in the evaluation of LAC, especially 
at levels ＞1 anti-Xa U/mL. Although some DRVVT and 
other phospholipid reagents contain polybrene, which can 
neutralize heparin, additional neutralizing agents might be 
still needed for some assays that do not contain polybrene. 
Some types of low molecular weight heparin can interfere 
with LAC results at levels as low as 0.25 anti-Xa U/mL. 
Patients with anti-Xa levels ＞1.0 U/mL were excluded from 
the final analysis.
This high prevalence of indeterminate results might have 
some clinical implications. We speculated that patients with 
indeterminate results might represent a distinct clinical, sero-
logical, or prognostic entity compared to those with negative 
tests from the same referred cohort. Patients in the in-
determinate group were older, with mean age of 54.5 years 
(vs. 47.2 years in the negative group, P=0.021). Although 
aPL antibodies were found among young, healthy, asympto-
matic subjects, the prevalence of these antibodies, including 
LAC, increased with age [13]. This higher prevalence could 
be also related to the common coexistence of chronic diseases 
in the older age group. Patients in the indeterminate group 
were more likely to be male. This differed from the very 
high percentage of female patients in the negative group. 
Female patients are more likely to be referred for LAC testing 
due to gynecological concerns or non-specific rheumatologic 
symptoms; thus, it is not unexpected to see a higher pro-
portion of women in the negative group. Regarding the 
Sapporo clinical criteria, DVT of the extremities was sig-
nificantly higher in the indeterminate group (P=0.044). LAC 
has been linked to lower extremity DVT both separately 
and in combination with other aPL antibodies. However, 
this association is still open for debate. De Groot et al. [14] 
showed that the presence of LAC, anti-β2 GPI antibodies, 
and antiprothrombin antibodies were risk factors for DVT 
in the general population. The strongest association was ob-
served with the presence of a combination of LAC and anti-β2 
GPI or antiprothrombin antibodies. In contrast, Sidelmann 
et al. [15] suggested that concurrent inflammation and a 
DVT episode might be the cause of such a high prevalence 
of LAC in these patients. One interesting clinical observation 
in our cohort is the statistically significant prevalence of 
superficial thrombophlebitis (ST) in the indeterminate group 
(P=0.005). In spite of its statistical significance, we do not 
think this observation has much clinical significance for 
several reasons. First, because ST is not included in the 
Sapporo criteria, reporting in this study was not limited 
to 5 years from the initial testing. Second, ST was poorly 
documented in the medical records, without documentation 
of instrumentation or DVT, specific time of the event, site, 
or number of episodes. Third, this might represent an associa-
tion with DVT in this group [16], rather than an independent 
association with indeterminate LAC. The prevalence of ob-
stetrical complications was very low in all 3 groups, mainly 
because the study center is not a large obstetrical referral 
center.
Different aPL antibodies have also been associated with 
malignancies [7] and immune mediated disorders like con-
nective tissue disorders, vasculitis [17], and inflammatory 
bowel disorders [18]. We speculated that indeterminate LAC 
results might be associated with such disorders. However, 
we failed to show any statistically significant difference in 
the prevalence of malignancies or immune disorders between 
the indeterminate LAC and negative result groups. In spite 
of the multiple significant variables between the 2 groups, 
we expected most of these to lose significance in multivariate 
analysis due to the heterogeneity of our population, small 
cohort size, and confounding factors. Therefore, when we 
used a multivariate model (age, gender, malignancy, immune 
disease, DVT, and warfarin therapy), none of these reached 
statistical significance.
Although clinical follow-up of the indeterminate LAC 
group was documented for a mean of 18.6±12.8 months 
(median=22 months), laboratory follow-up was much less 
frequent. Of the 65 patients, only 19 (29%) had more than 
1 test documented within 2 years before or after study 
enrollment. Two patients had incomplete repeated tests, and 
1 test had a very high heparin level that could not be 
neutralized. Of the 16 patients with complete repeat testing, 
6 (37.5%) had persistent indeterminate results, 6 had negative 
results (37.5%), and 4 (25%) had documented positive LAC 
profiles. Therefore, 10 of the 16 patients with repeated LAC 
testing had changed profile results during the 18-month 
follow-up period. However, we were not able to determine 
a trend of change in profile upon retesting, nor predictors 
for change due to the small number of patients with follow-up 
testing. We could not attribute the poor retesting rate to 
weak clinical suspicion, because these patients had similar 
clinical manifestations compared to those with positive tests. Korean J Hematol 2011;46:239-43.
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The Sapporo and revised ISTH criteria recommend retesting 
for patients with positive LAC on a second occasion greater 
than 12 weeks after the initial testing [6, 11]. In contrast, 
the clinical indication for repeat testing in patients who 
have indeterminate LAC results is not well established. Since 
50% of our cohort that was retested had a change in their 
LAC profile status, repeating LAC testing in patients with 
clinical suspicion of thrombosis but indeterminate LAC re-
sults may be considered to establish or refute a diagnosis 
of LAC.
There is wide variability in the way LAC testing is per-
formed between medical centers. Many centers perform LAC 
testing using an algorithmic approach with initial screening 
assays followed by mixing studies only if 1 or more screening 
test is abnormal; PL neutralization steps are only performed 
for samples with positive mixing studies. The testing method-
ology utilized in this study was different in that all screening, 
mixing, and PL tests were performed and the results were 
examined as a panel. It is clear from our results that abnormal 
PL-D tests can be seen in patients with normal screening 
tests and negative mixing studies.
This study has several weaknesses, including the retro-
spective design, very low retesting rate, heterogeneous re-
ferred patient population, and limited follow-up. Neverthe-
less, this study is the first to document a high prevalence 
of indeterminate results and to test its clinical significance. 　
In conclusion, indeterminate results are common among pa-
tients referred for LAC testing. Compared to patients with 
negative results, patients with indeterminate results are more 
likely to have a history of DVT, superficial thrombosis, and 
MI; however, none of the clinical variables reached statistical 
significance in a multivariate model. On the other hand, 
patients in the indeterminate group shared demographic and 
clinical profiles with those in the positive results group. 
This highlights the need to study the clinical significance 
of indeterminate LAC results in a prospective study.
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